Abstract
Blockade of the CTLA-4 and PD-1 inhibitory pathways in T cells via the administration of neutralizing antibodies at the time of interleukin (IL)-15 therapy markedly enhanced the survival of tumor-bearing mice as compared with those receiving IL-15 alone or IL-15 in combination with just one of the antibodies.
©2010 AACR.
MeSH terms
-
Animals
-
Antibodies, Neutralizing / administration & dosage
-
Antibodies, Neutralizing / pharmacology*
-
Antigens, CD / immunology
-
Antigens, CD / metabolism
-
Antigens, CD / physiology
-
Antigens, Differentiation / immunology
-
Antigens, Differentiation / metabolism
-
Antigens, Differentiation / physiology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
CTLA-4 Antigen
-
Cell Line, Tumor
-
Disease Models, Animal
-
Drug Evaluation, Preclinical
-
Drug Synergism
-
Immune Tolerance / drug effects*
-
Immune Tolerance / immunology
-
Immunotherapy / methods
-
Interleukin-15 / therapeutic use*
-
Mice
-
Models, Biological
-
Neoplasm Metastasis
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Neoplasms / mortality
-
Neoplasms / pathology
-
Programmed Cell Death 1 Receptor
-
Signal Transduction / drug effects
-
Signal Transduction / immunology
-
Treatment Outcome
Substances
-
Antibodies, Neutralizing
-
Antigens, CD
-
Antigens, Differentiation
-
CTLA-4 Antigen
-
Ctla4 protein, mouse
-
Interleukin-15
-
Pdcd1 protein, mouse
-
Programmed Cell Death 1 Receptor